+1-888-308-5802     
News Contact Us

Calithera begins clinical study of drug combination in cancer patients

Author : Shikha Sinha | Published Date : 2019-07-04 

Calithera Biosciences, a clinical-stage biotech company focused on developing small molecule drugs to treat cancer and life-threatening diseases, recently announced that it has treated the first patient in an open-label Phase 1/2 clinical trial of Glutaminase inhibitor telaglenastat combined with Pfizer’s CDK 4/6 inhibitor palbociclib, alternatively called Ibrance.

The study will be evaluating the anti-tumor activity and safety of telaglenastat-pluspalbociclib combination in patients with KRAS-mutated non-small cell lung cancer (NSCLC) and KRAS-mutated colorectal cancer (CRC).

President and chief executive officer at Calithera, Susan Molineaux said that preclinical data indicate palbociclib and telaglenastat perform synergistically in KRAS-mutated tumors, which will offer a different approach to the challenges that are associated with the treatment of KRAS-mutated cancers.

The company is looking forward to launching a second trial with Pfizer and expect that the combination of telaglenastat and palbociclib will fill a major treatment gap for both the medical professionals and patients, Molineaux  mentioned.

Apparently, telaglenastat is designed in a way that it is capable of blocking glutamine consumption in tumor cells. Telaglenastat reportedly showed synergistic antitumor effects in a preclinical KRAS-mutated cancer models. It was used with CDK4/6 inhibitors like palbociclib, that enhanced blocking of cancer cell proliferation and cell cycle arrest.

According to reliable sources, the Phase 1/2 clinical trial will be evaluating the anti-tumor activity and the safety of the combination of telaglenastat and palbociclib in patients suffering with locally advanced KRAS-mutated NSCLC or KRAS-mutated CRC, both of which are intolerant to standard therapies and refractory.

For the record, Calithera has initiated a second trial that is part of the Pfizer’s current clinical trial agreement. The first trial is reportedly testing the combination of telaglenastat with PARP inhibitor talazaporib. It is underway in patients with triple negative breast cancer ( TNBC), CRC and renal cell carcinoma (RCC). The first trial begun enrolling patients in March and Pfizer will provide talazoparib and palbociclib along with monetary support as per the agreement.

Source Credit- http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-initiates-phase-12-trial-telaglenastat-0?field_nir_news_date_value%5bmin%5d=

About Author

Shikha Sinha

Shikha Sinha

Shikha Sinha currently pens down content for fractovia.org, a news platform which provides the latest business highlights and industry trends. Shikha also is a contributor on various other online media websites where she writes informative, research-oriented content spanning the retail, healthcare, F&B, and technology sectors. As her first stint in writing, Shikha was an active contributor on Yahoo Voices where she penned down creative and imaginative pieces. She holds a Bachelor of Technology degree in Electrical and Electronics Engineering. She can be contacted at- [email protected] | https://twitter.com/shikhas999

Related News

Clio raises $250 million in a Series D funding by TCV and JMI Equity

Published Date: 2019-09-06         Author: Shikha Sinha

The cloud-based legal technology startup hits a historic mark in future of legal industry with this investment. Clio, a leading legal software company has recently announced that it has bagged US$250 million in Series D funding from American equity firms JMI Equity and TCV. According to sour... Read More

Co-working firm Spacious the latest in WeWork’s acquisition spree

Published Date: 2019-08-29         Author: Shikha Sinha

New York-based co-working business, The We Company, formerly known as WeWork, has today announced its acquisition of rival start-up Spacious. The company, formed three years ago, is focused on converting restaurants closed during the day into efficient spaces for co-working. WeWork is a part of many... Read More

SoftBank in talks to invest $150M in Dailyhunt and $400M in Lenskart

Published Date: 2019-08-27         Author: Shikha Sinha

SoftBank is expected to lead a $250 million round with private equity major Carlyle for Dailyhunt   South American conglomerate Synergy Group also hopes to invest in India’s Jet Airways. SoftBank Group Corp., a Japanese multinational conglomerate, is reportedly in talks to clo... Read More

© 2020 Fractovia. All Rights Reserved